<DOC>
	<DOCNO>NCT03061513</DOCNO>
	<brief_summary>The purpose study find whether ubiquinol well tolerate , affect symptom Parkinson 's Disease change energy level brain . Subjects randomize take ubiquinol placebo neurological evaluation , magnetic resonance spectroscopy ( MRS ) blood test biological marker take study .</brief_summary>
	<brief_title>Ubiquinol Parkinson 's Disease : Safety , Tolerability , Effects Upon Oxidative Damage Mitochondrial Biomarkers</brief_title>
	<detailed_description>Multiple line evidence implicate abnormal energy metabolism deficient mitochondrial function Parkinson 's disease , present unique target therapy . A pilot study ubiquinol PD therefore undertaken determine effect upon physiologic measure mitochondrial metabolic function . The incorporation neuroimaging biomarker particularly important , since change would demonstrate ability achieve Central Nervous System ( CNS ) access formulation , accompany meaningful neurophysiologic effect . Hydrogen Proton Magnetic Resonance Spectroscopy Imaging ( 1H MRSI ) technique provide insight metabolism several endogenous brain compound , notably N-acetyl-L-aspartate ( NAA ) , choline-containing compound ( Cho ) , creatine phosphocreatine ( Cr ) . A number study mitochondrial function firmly establish utility 1H MRSI probe potential mitochondrial energy metabolism dysfunction , primary mitochondrial disorder , also PD . This pilot study therefore design test whether oral ubiquinol affect cerebral index mitochondrial dysfunction , measure 1H MRSI patient Parkinson 's disease , gather preliminary information safety tolerability ubiquinol individual PD .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>diagnosis PD accord Untied Kingdom ( UK ) Brain Bank Criteria , confirm Movement Disorders neurologist ; age 4075 year ; diagnosis within 5 year study participation ; PD medication able remain stable dos opinion enrol investigator ; able undergo MRI ; absence significant medical , psychiatric , neurological disease ; absence dementia MiniMental State Examination ( MMSE ) &gt; 26. failure meet diagnosis criterion ; time since diagnosis &gt; 5 year study participation ; PD medication predict remain stable dos opinion enrol investigator ; unable undergo MRI ; unable comply informed consent process ; presence significant medical , psychiatric ( include major depressive disorder ) neurological ( include epilepsy , brain tumor , stroke ) disease ; diagnosis dementia and/or MMSE 26 low ; possibility pregnancy ( negative test require woman childbearing age ) ; take medication include antipsychotic agent dopamine block antiemetic agent ; take Coenzyme Q10 ; participation another clinical trial within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>ubiquinol</keyword>
	<keyword>CoQ10</keyword>
	<keyword>magnetic resonance spectroscopy</keyword>
	<keyword>lactate</keyword>
	<keyword>glutathione</keyword>
</DOC>